DNA vaccines are used for producing a specific immune response against a disease, these are third-generation vaccines. DNA vaccines use genes from a bacteria or virus in order to stimulate the immune system. DNA vaccines contain circular DNA plasmid that that are used for encoding protein antigens and produce an immune response against a disease. DNA vaccines are a safe option and they can be used as inactivated vaccines and help in treating various viral diseases. These vaccines can be used to produce immune responses against various viruses and these can be produced rapidly. They can be used to generate cell-mediated and humoral immune responses.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/4987
Impact of COVID 19:
COVID-19 has led to an increase in the efforts for producing safer vaccines in order to treat various diseases, this is expected to boost the growth of the global human DNA vaccines market during the forecast period. For instance, Medical Life Sciences published a report in February 2021, mentioning that around 250 vaccines have been developed for battling COVID-19, out of this around 181 vaccines are in preclinical development stage and 69 vaccines are still undergoing clinical testing, amongst these 10 of them happen to be DNA vaccines.
Moreover, an American biotechnology company, INOVIO has received approval for carrying out the phase III efficacy trials of INO-4800, a COVID-19 DNA vaccine, owing to the promising results of the earlier trials. INO-4800 is a nucleic-acid based vaccine that remains stable at room temperature and has a shelf life of five years at normal refrigeration temperature. The vaccine is can be transported or stored easily as it does not need to be frozen.
Human DNA vaccines are more stable, require less time for production, safe, cost efficient, easy to transport and they can easily be included in the immunostimulatory sequences as compared to other vaccines, these features contribute to fuel the growth of the global human DNA vaccines market during the forecast period.
Furthermore, the positive results of the clinical trials of DNA vaccines are expected to augment the growth of the global human DNA vaccines market during the forecast period. For instance, world’s first DNA COVID-19 vaccine ZyCoV-D by Zydus Cadila was approved in India in August 2021. According to an interim study, three-doses of ZyCoV-D vaccine helped in preventing symptomatic disease in 66% of vaccinated individuals.
Moreover, increasing incidences of infectious diseases like hepatitis, cancer and others and the increasing number of resistant pathogens are the major factors for boosting the growth of the global human DNA vaccines market.
Rise in the stringent regulatory system for product approval and decrease in the adoption of DNA vaccines in many developing nations is expected to hinder the growth of the global human DNA vaccines market during the forecast period. However, intrinsic low immunogenicity is the major obstruction in the development of DNA vaccine.
Furthermore, risks related to gene therapy are also a limiting factor in hampering the growth of the global human DNA vaccines market during the forecast period. Targeting of wrong cell, unwanted immune system reaction and an infection caused by a virus are some of the potential risks which can severely hamper the growth of the global human DNA vaccines market over the forecast period.
North America is expected to witness robust growth in the global human DNA vaccines market over the forecast period, due to rapid increase in cases of HIV, hepatitis, cancer and increased developments in the immunology & molecular biology. Increase in the number of government investments and rise in the number of antibiotic resistant pathogens has created the need for low-cost and effective vaccinations. For instance, Biden Administration declared that they will be investing US$ 10 Billion for making COVID-19 vaccines more accessible and also help in building confidence against vaccines in high-risk communities.
Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/4987
- Recombinant Protein Vaccine
- Gene Based Vaccine
- Human Papillomavirus
By End User
- Hospitals & Specialty Clinics
- Ambulatory Surgical Centers
- North America
- Latin America
- Asia Pacific
- Middle East
Key players active in the global human DNA vaccines market are GeoVax, GlaxoSmithKline plc, Valneva SE, Serum Institute of India Pvt. Ltd, Biomay AG, Bharat Biotech., VGXI, Inc., Indian Immunologicals Limited, Ichor Medical Systems., Merck & Co., Inc, General Electric, GREEN CROSS CORP, Inovio Pharmaceuticals, Inc., Novartis AG, Immunomic Therapeutics, Inc, Sanofi, Pfizer Inc, Zoetis and Aldevron, AnGes.
Reasons to buy this Human DNA Vaccines Market Report
◘ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Human DNA Vaccines Market
◘ Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Human DNA Vaccines Market
◘ Leading company profiles reveal details of key Human DNA Vaccines Market players emerging five operations and financial performance
◘ Add weight to presentations and pitches by understanding the future growth prospects of the emerging Human DNA Vaccines Market with five year historical forecasts
◘ Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Human DNA Vaccines Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Human DNA Vaccines Market are also given.
Buy This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/4987
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Human DNA Vaccines Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Human DNA Vaccines Industry Impact
Chapter 2 Global Human DNA Vaccines Competition by Types, Applications, and Top Regions and Countries
2.1 Global Human DNA Vaccines (Volume and Value) by Type
2.3 Global Human DNA Vaccines (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Human DNA Vaccines Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Human DNA Vaccines Market Analysis
Chapter 6 East Asia Human DNA Vaccines Market Analysis
Chapter 7 Europe Human DNA Vaccines Market Analysis
Chapter 8 South Asia Human DNA Vaccines Market Analysis
Chapter 9 Southeast Asia Human DNA Vaccines Market Analysis
Chapter 10 Middle East Human DNA Vaccines Market Analysis
Chapter 11 Africa Human DNA Vaccines Market Analysis
Chapter 12 Oceania Human DNA Vaccines Market Analysis
Chapter 13 South America Human DNA Vaccines Market Analysis
Chapter 14 Company Profiles and Key Figures in Human DNA Vaccines Business
Chapter 15 Global Human DNA Vaccines Market Forecast (2022-2028)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027